Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F25%3A00643403" target="_blank" >RIV/61388971:_____/25:00643403 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00141882 RIV/00216208:11130/25:10492219 RIV/65269705:_____/25:00081479 RIV/00064211:_____/25:W0000034 RIV/00064203:_____/25:10492219
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2460578" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2460578</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/09546634.2025.2460578" target="_blank" >10.1080/09546634.2025.2460578</a>

Result language
angličtina
Original language name
Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
Original language description
In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases

Project
<a href="/en/project/NU20-05-00038" target="_blank" >NU20-05-00038: The role of microbiome in the development of atopic dermatitis and food allergy in infants and toddlers</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)